BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33620289)

  • 1. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
    Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
    Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018.
    Kim YY; Kim MJ; Kim EH; Roh YH; An C
    Radiology; 2019 Apr; 291(1):72-80. PubMed ID: 30694166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 4. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
    Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
    Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.
    van der Pol CB; Lim CS; Sirlin CB; McGrath TA; Salameh JP; Bashir MR; Tang A; Singal AG; Costa AF; Fowler K; McInnes MDF
    Gastroenterology; 2019 Mar; 156(4):976-986. PubMed ID: 30445016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study.
    Ludwig DR; Romberg EK; Fraum TJ; Rohe E; Fowler KJ; Khanna G
    Pediatr Radiol; 2019 May; 49(6):746-758. PubMed ID: 31069473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Lee S; Kim YY; Shin J; Hwang SH; Roh YH; Chung YE; Choi JY
    J Am Coll Radiol; 2020 Oct; 17(10):1199-1206. PubMed ID: 32640250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 13. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014.
    Fraum TJ; Tsai R; Rohe E; Ludwig DR; Salter A; Nalbantoglu I; Heiken JP; Fowler KJ
    Radiology; 2018 Jan; 286(1):158-172. PubMed ID: 28853673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
    Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
    Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
    Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
    Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
    Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
    AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
    [No Abstract]   [Full Text] [Related]  

  • 20. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.